|
|
IMPORTANT NIMOTOP ANNOUNCEMENT
Bayer HealthCare Pharmaceuticals will discontinue marketing Nimotop® (nimodipine) capsules — unit dose 30's NDC 00026-2855-48 and unit dose 100's NDC 00026-2855-70 — for subarachnoid hemorrhage (SAH) in the United States. The company made this decision based on the availability of generic treatment alternatives and diminished market demand for the Nimotop brand in the U.S. The decision to discontinue the marketing of Nimotop is not the result of safety or efficacy issues.
Based on product expiration dates, we will fulfill Nimotop orders to wholesalers until the end of October. Generic nimodipine is available, and we encourage you to discuss treatment alternatives with your patients.
For those patients who may be receiving Nimotop through Bayer's Patient Assistance Program (PAP), we are committed to supporting the program through the end of 2008. Please contact the PAP program at (866) 575-5002 if you have any questions specific to the Patient Assistance Program.
On behalf of Bayer HealthCare, we regret any inconvenience this business decision may have on your practice, and we very much appreciate your support for Nimotop and the patients we have had the honor of serving over the years. Should you have any questions, please call Bayer Customer Service (877) 229-3750 or Bayer Medical Communications (888) 842-2937 (option 3, option 7).
DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY
(See
WARNINGS and DOSAGE AND ADMINISTRATION.) |
© Bayer HealthCare Pharmaceuticals.
Bayer HealthCare Pharmaceuticals
6 West Belt
Wayne, NJ 07470
The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the US.
Site development provided by H2.
|
|
|
